Glucose in the dialysate: Historical perspective and possible implications?

Hemodialysis International

Volumn 12, Issue 2, 2008, Pages 221-226

  Sharma, Rajiv ^a   Rosner, Mitchell H ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Glucose; Hemodialysis; Inflammation; Interleukins

Indexed keywords

ADVANCED GLYCATION END PRODUCT; DIALYSIS FLUID; GLUCOSE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CHRONIC INFLAMMATION; CONCENTRATION (PARAMETERS); ENERGY EXPENDITURE; EVIDENCE BASED MEDICINE; GLUCOSE BLOOD LEVEL; HEMODIALYSIS; HUMAN; HYPERGLYCEMIA; INFLAMMATION; KIDNEY FAILURE; METABOLIC PARAMETERS; MORBIDITY; MORTALITY; NONHUMAN; ULTRAFILTRATION;

GLUCOSE; HEMODIALYSIS SOLUTIONS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; HYPERGLYCEMIA; INFLAMMATION; KIDNEY FAILURE; MODELS, BIOLOGICAL; RENAL DIALYSIS;

EID: 41849141263     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2008.00256.x     Document Type: Article

References (33)

1. Parsons FM, Stewart WK. The composition of dialysis fluid. In: Drukker W, Parsons FM, Maher JF eds. Replacement of Renal Function by Dialysis. 2nd ed. Boston, MA: Maritnus, Nijhoff Publishers; 1983:148-170.
2. Sam R, Vaseemuddin M, Leong WH, et al. Composition and clinical use of hemodialysates. Hemodial Int. 2006; 10: 15-28.
3. Wathen RL, Keshaviah P, Hommeyer P, et al. The metabolic effects of hemodialysis with and without glucose in the dialysate. Am J Clin Nutr. 1978; 31: 1870-1875.
4. Ward RA, Wathen RL, Williams TE, Harding GB. Hemodialysate composition and intradialytic metabolic, acid-base and potassium changes. Kidney Int. 1987; 32: 129-135.
5. Fischbach M, Terzic J, Bitoun Cohen C, et al. Glucose-charged dialysate for children on hemodialysis: Acute dialytic changes. Pediatr Nephrol. 1988; 12: 311-314.
6. Borah M, Schoenfeld PY, Gotch FA, et al. Nitrogen balance during intermittent dialysis therapy of uremia. Kidney Int. 1978; 14: 491-500.
7. Gutierrez A, Bergstrom J, Alvestrand A. Hemodialysis-associated protein catabolism with and without glucose in the dialysis fluid. Kidney Int. 1994; 46: 814-822.
8. Takahashi A, Kubota T, Shibahara N, et al. The mechanism of hypoglycemia caused by hemodialysis. Clin Nephrol. 2004; 62: 362-368.
9. Jackson MA, Holland MR, Nicholas J, et al. Occult hypoglycemia caused by hemodialysis. Clin Nephrol. 2000; 53: 235-236.
10. Jackson MA, Holland MR, Nicholas J, et al. Hemodialysis-induced hypoglycemia in diabetic patients. Clin Nephrol. 2000; 54: 30-34.
11. Simic-Ogrizovic S, Backus G, Mayer A, et al. The influence of different glucose concentrations in haemodialysis solutions on metabolism and blood pressure stability in diabetic patients. Int J Artif Organs. 2001; 24: 863-869.
12. Burmeister JE, Scapini A, da Rosa Miltersteiner D, et al. Glucose-added dialysis fluid prevents asymptomatic hypoglycemia in regular hemodialysis. Nephrol Dial Transplant. 2007; 22: 1184-1189.
13. Kaysen GA, Eiserich JP. Characteristics and effects of inflammation in end-stage renal disease. Semin Dial. 2003; 16: 438-446.
14. Stenvinkel P, Alvestrand P. Inflammation in end-stage renal disease: Sources, consequences and therapy. Semin Dial. 2002; 15: 330-338.
15. Kaysen GA. The microinflammatory state in uremia: Causes and potential consequences. J Am Soc Nephrol. 2001; 2: 1549-1557.
16. Odetti P, Cosso L, Pronzato MA, et al. Plasma advanced glycosylation end-products in maintenance hemodialysis patients. Nephrol Dial Transplant. 1995; 10: 2110-2113.
17. Loughrey CM, Young IS, Lightbody JH, et al. Oxidative stress in hemodialysis. QJM. 1994; 87: 679-683.
18. Stenvinkel P, Ketteler M, Johnson RJ, et al. IL-10, IL-6 and TNF-α: Central factors in the altered cytokine network of uremia-the good, the bad, and the ugly. Kidney Int. 2005; 67: 1216-1233.
19. Vlassara H, Palace MR. Diabetes and advanced glycation endproducts. J Intern Med. 2002; 251: 87-101.
20. Greene DA, Lattimer SA, Sima AA. Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications. N Engl J Med. 1987; 316: 599-606.
21. Kapor-Drezgic J, Zhou X, Babazono T, et al. Effect of high glucose on mesangial cell protein kinase C- δ and - ε is polyol pathway-dependent. J Am Soc Nephrol. 1999; 10: 1193-1203.
22. Schrijvers BF, De Vriese AS, Flyvbjerg A. From hyperglycemia to diabetic kidney disease: The role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr Rev. 2004; 25: 971-1010.
23. Shanmugam N, Reddy MA, Guha M, Natarajan R. High glucose-induced expression of proinflammatory cytokine and chemokine genes in monocytic cells. Diabetes. 2003; 52: 1256-1264.
24. Morohoshi M, Fujisawa K, Uchimura I, Numano F. Glucose-dependent interleukin 6 and tumor necrosis factor production by human peripheral blood monocytes in vitro. Diabetes. 1996; 45: 954-959.
25. Lu L, Zhang Q, Pu LJ, et al. Elevation of tumor necrosis factor-alpha, interleukin-1beta and interleukin-6 levels in aortic intima of Chinese Guizhou minipigs with streptozotocin-induced diabetes. Chin Med J. 2007; 120: 479-484.
26. Ugochukwu NH, Figgers CL. Caloric restriction inhibits up-regulation of inflammatory cytokines and TNF-alpha, and activates IL-10 and haptoglobin in the plasma of streptozotocin-induced diabetic rats. J Nutr Biochem. 2007; 18: 120-126.
27. de Rekeneire N, Peila R, Ding J, et al. Diabetes, hyperglycemia, and inflammation in older individuals. Diabetes Care. 2006; 29: 1902-1908.
28. Esposito K, Nappo F, Marfella R, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: Role of oxidative stress. Circulation. 2002; 106: 2067-2072.
29. Ategbo JM, Grissa O, Yessoufou A, et al. Modulation of adipokines and cytokines in gestational diabetes and macrosomia. J Clin Endocrinol Metab. 2006; 91: 4137-4143.
30. Wasmuth HE, Kunz D, Graf J, et al. Hyperglycemia at admission to the intensive care unit is associated with elevated serum concentrations of interleukin-6 and reduced ex vivo secretion of tumor necrosis factor-α. Crit Care Med. 2004; 32: 1109-1114.
31. Welten AG, Schalkwijk CG, ter Wee PM, et al. Single exposure of mesothelial cells to glucose degradation products (GDPs) yields early advanced glycation end-products (AGEs) and a proinflammatory response. Perit Dial Int. 2003; 23: 213-221.
32. Pecoits-Filho R, Carvalho MJ, Stenvinkel P, et al. Systemic and intraperitoneal interleukin-6 system during the first year of peritoneal dialysis. Perit Dial Int. 2006; 26: 53-63.
33. Jaar BG, Coresh J, Plantinga LC, et al. Comparing the risk for death with peritoneal dialysis and hemodialysis in a national cohort of patients with chronic kidney disease. Ann Intern Med. 2005; 143: 174-183.